Yeonhee Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yeonhee Kim has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Woo-Jung Song
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul
7 shared publications - Ha-Kyeong Won
Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju 28644, Korea
3 shared publications - Noeul Kang
Division of Allergy, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul South Korea
3 shared publications - Young-Chan Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
3 shared publications Byung-Jae Lee
2 shared publicationsHwa Young Lee
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Interpretive framework for Cough Hypersensitivity Questionnaire scores in chronic cough
Extract Chronic cough (>8 weeks) is a prevalent condition that substantially impairs quality of life (QoL) [1, 2]. While some cases are attributable to identifiable etiologies, chronic cough that remains unexplained or persists despite treatment of associated conditions represents an important unmet medical need [3]. Cough hypersensitivity has recently emerged as a key pathophysiological feature and treatable trait in these patients [4–7].
- 23 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessInterpretive framework for Cough Hypersensitivity Questionnaire scores in chronic cough
Extract Chronic cough (>8 weeks) is a prevalent condition that substantially impairs quality of life (QoL) [1, 2]. While some cases are attributable to identifiable etiologies, chronic cough that remains unexplained or persists despite treatment of associated conditions represents an important unmet medical need [3]. Cough hypersensitivity has recently emerged as a key pathophysiological feature and treatable trait in these patients [4–7].
- Open Access
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (4) , 507-524
KAAACI Consensus Document on the Goals and Standards of Chronic Cough Clinics in Korea: A Delphi Study
Kim MY, et al. Allergy Asthma Immunol Res. 2026 Jul;18(4):507-524. https://doi.org/10.4168/aair.2026.18.4.507
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (4) , 507-524
Open AccessKAAACI Consensus Document on the Goals and Standards of Chronic Cough Clinics in Korea: A Delphi Study
Kim MY, et al. Allergy Asthma Immunol Res. 2026 Jul;18(4):507-524. https://doi.org/10.4168/aair.2026.18.4.507
- Open Access
- 7 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Disease finds its identity with treatment in the real world: the use of gefapixant in chronic cough
Refractory or unexplained chronic cough (RUCC) is a disease without a proper name [1, 2]. Historically, it has been a diagnosis of exclusion, reflecting the challenges of classification, and the broader struggle to understand and treat this condition [3]. Recent studies suggest that approximately 10–50% of adults seeking specialist care for chronic cough may turn out to have refractory cough, with a disease duration of 5–10 years before receiving appropriate recognition [4, 5]. RUCC refers to a persistent cough despite extensive evaluation and treatment of underlying causes such as asthma, gastro-oesophageal reflux disease or upper airway cough syndrome. The lack of a clear disease identity worsens patients' suffering beyond their physical symptoms, leading to health anxiety, sleep disruption and social isolation [6, 7]. Patients often face scepticism from healthcare providers and society, frequently being dismissed as having “just a cough” or being labelled as anxious [8].
- 7 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Open AccessDisease finds its identity with treatment in the real world: the use of gefapixant in chronic cough
Refractory or unexplained chronic cough (RUCC) is a disease without a proper name [1, 2]. Historically, it has been a diagnosis of exclusion, reflecting the challenges of classification, and the broader struggle to understand and treat this condition [3]. Recent studies suggest that approximately 10–50% of adults seeking specialist care for chronic cough may turn out to have refractory cough, with a disease duration of 5–10 years before receiving appropriate recognition [4, 5]. RUCC refers to a persistent cough despite extensive evaluation and treatment of underlying causes such as asthma, gastro-oesophageal reflux disease or upper airway cough syndrome. The lack of a clear disease identity worsens patients' suffering beyond their physical symptoms, leading to health anxiety, sleep disruption and social isolation [6, 7]. Patients often face scepticism from healthcare providers and society, frequently being dismissed as having “just a cough” or being labelled as anxious [8].
- Open Access
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Treatable traits in chronic cough: a prospective evaluation for predicting cough persistence
Background: The concept of treatable traits has been proposed for managing chronic cough; however, evidence supporting its clinical utility remains limited. This study investigated the relationship between baseline traits and cough persistence in a prospective registry of patients with chronic cough. Methods: We analysed data from 426 patients with chronic cough enrolled in the Korean Chronic Cough Registry. 11 potential treatable traits were assessed at baseline. The primary outcome was cough persistence, defined as a cough severity visual analogue scale (VAS) score >20 at the last follow-up visit. Results: After a median follow-up of 12 months (interquartile range: 6–24 months), 215 patients (50.5%) had persistent cough (VAS >20 mm). The most prevalent traits were sputum production (60.5%), cough hypersensitivity symptoms (41.8%) and type 2 inflammation (39.1%). Among baseline traits, only cough hypersensitivity symptoms were significantly associated with cough persistence (p=0.024). In multivariate analysis, cough hypersensitivity symptoms (adjusted OR 1.78, 95% CI 1.15–2.78; p=0.010) and older age (≥60 years) (adjusted OR 2.07, 95% CI 1.34–3.20; p=0.001) were independently associated with cough persistence. Conclusions: These findings suggest that cough hypersensitivity symptoms are associated with long-term outcomes of chronic cough. Further studies are needed to validate the role of treatable traits in chronic cough management and to better understand factors associated with cough persistence.
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Open AccessTreatable traits in chronic cough: a prospective evaluation for predicting cough persistence
Background: The concept of treatable traits has been proposed for managing chronic cough; however, evidence supporting its clinical utility remains limited. This study investigated the relationship between baseline traits and cough persistence in a prospective registry of patients with chronic cough. Methods: We analysed data from 426 patients with chronic cough enrolled in the Korean Chronic Cough Registry. 11 potential treatable traits were assessed at baseline. The primary outcome was cough persistence, defined as a cough severity visual analogue scale (VAS) score >20 at the last follow-up visit. Results: After a median follow-up of 12 months (interquartile range: 6–24 months), 215 patients (50.5%) had persistent cough (VAS >20 mm). The most prevalent traits were sputum production (60.5%), cough hypersensitivity symptoms (41.8%) and type 2 inflammation (39.1%). Among baseline traits, only cough hypersensitivity symptoms were significantly associated with cough persistence (p=0.024). In multivariate analysis, cough hypersensitivity symptoms (adjusted OR 1.78, 95% CI 1.15–2.78; p=0.010) and older age (≥60 years) (adjusted OR 2.07, 95% CI 1.34–3.20; p=0.001) were independently associated with cough persistence. Conclusions: These findings suggest that cough hypersensitivity symptoms are associated with long-term outcomes of chronic cough. Further studies are needed to validate the role of treatable traits in chronic cough management and to better understand factors associated with cough persistence.
- Open Access
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Predictors of asthma exacerbation between high and low blood eosinophil counts
Background: Despite treatment advances, managing asthma remains challenging owing to variability in response across different type 2 inflammation phenotypes. We aimed to compare the differences in pre-treatment profiles related to 12-month asthma exacerbation in patients with baseline high and low blood eosinophil count (BEC) levels. Methods: This study included 438 and 231 patients with asthma with pre-treatment BEC levels >300 cells·μL−1 (high BEC) and −1 (low BEC), respectively, and no history of systemic corticosteroid use. 40 pre-treatment variables were collected and exacerbation occurrences were tracked over 12 months. The least absolute shrink and selection operator (LASSO) regression was applied to identify key variables for predicting exacerbation occurrences in the two BEC groups. Results: Baseline characteristics, including impaired lung function, female sex and sensitivity to stress as an asthma trigger were important predictors of exacerbation in both BEC groups. Significant characteristics related to exacerbation in the high-BEC group included high pre-treatment BEC levels, history of smoking, sensitivity to tobacco smoke and allergic-related conditions. In contrast, key characteristics associated with exacerbation in the low-BEC group included high baseline peripheral neutrophil counts, current smokers, history of tuberculosis and the use of long-acting β2 agonists plus long-acting muscarinic agonists. The prediction model for 12-month exacerbation using baseline characteristics had stronger predictive power in the low-BEC group than the high-BEC group. Conclusion: The exacerbation profiles of patients with asthma with high and low pretreatment BEC levels share some common characteristics despite substantial differences.
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Open AccessPredictors of asthma exacerbation between high and low blood eosinophil counts
Background: Despite treatment advances, managing asthma remains challenging owing to variability in response across different type 2 inflammation phenotypes. We aimed to compare the differences in pre-treatment profiles related to 12-month asthma exacerbation in patients with baseline high and low blood eosinophil count (BEC) levels. Methods: This study included 438 and 231 patients with asthma with pre-treatment BEC levels >300 cells·μL−1 (high BEC) and −1 (low BEC), respectively, and no history of systemic corticosteroid use. 40 pre-treatment variables were collected and exacerbation occurrences were tracked over 12 months. The least absolute shrink and selection operator (LASSO) regression was applied to identify key variables for predicting exacerbation occurrences in the two BEC groups. Results: Baseline characteristics, including impaired lung function, female sex and sensitivity to stress as an asthma trigger were important predictors of exacerbation in both BEC groups. Significant characteristics related to exacerbation in the high-BEC group included high pre-treatment BEC levels, history of smoking, sensitivity to tobacco smoke and allergic-related conditions. In contrast, key characteristics associated with exacerbation in the low-BEC group included high baseline peripheral neutrophil counts, current smokers, history of tuberculosis and the use of long-acting β2 agonists plus long-acting muscarinic agonists. The prediction model for 12-month exacerbation using baseline characteristics had stronger predictive power in the low-BEC group than the high-BEC group. Conclusion: The exacerbation profiles of patients with asthma with high and low pretreatment BEC levels share some common characteristics despite substantial differences.
- Open Access
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (4) , 405-408
Beyond Clinical Remission: Redefining Disease Control in Severe Asthma?
Kim Y, et al. Allergy Asthma Immunol Res. 2025 Jul;17(4):405-408. https://doi.org/10.4168/aair.2025.17.4.405
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (4) , 405-408
Open AccessBeyond Clinical Remission: Redefining Disease Control in Severe Asthma?
Kim Y, et al. Allergy Asthma Immunol Res. 2025 Jul;17(4):405-408. https://doi.org/10.4168/aair.2025.17.4.405
- Open Access
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (3) , 304-316
How Will a Treatable Traits Approach Reshape Clinical Practice in Chronic Cough?
Kim Y, et al. Allergy Asthma Immunol Res. 2025 May;17(3):304-316. https://doi.org/10.4168/aair.2025.17.3.304
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (3) , 304-316
Open AccessHow Will a Treatable Traits Approach Reshape Clinical Practice in Chronic Cough?
Kim Y, et al. Allergy Asthma Immunol Res. 2025 May;17(3):304-316. https://doi.org/10.4168/aair.2025.17.3.304